Employees prefer the kitchen table to the boardroom. Photo by Maskot/Getty

For some, working from home is starting to look like the new normal. But whether your office is gearing up for reopening or you're looking at taking calls from your couch for the foreseeable future, one thing is for sure: Texans love that WFH life.

Finance website RealBusinessSavings.com recently surveyed 3,500 American employees to evaluate their attitudes about offices in the current circumstances, and the results showed an overwhelming preference for our makeshift home desks.

The average American employee would take a $316 pay cut per month in order to continue working from home after lockdown, with Texans specifically willing to give up $278 each month to avoid going back to their place of work.

Nationally, 57 percent of employees say they will request to continue working from home to avoid contracting coronavirus in the workplace. One in 10 are happy to be far away from office politics, and two in three say they have been more productive working from home.

When it comes to reasons people prefer to continue working from home, 30 percent of employees say saving money on transportation is the best thing, followed by no daily commute (28 percent). An additional 22 percent say the best part is saving money on lunch and afterwork drinks, while 8 percent said their favorite part is not having to wear business attire (hooray for yoga pants!).

Broken down across the country, it appears Californians are most keen on keeping their WFH routines after lockdown, as the average employee there would forfeit $495 of their salary in order to continue to do so. Comparatively, Hawaii employees are ready to go back to the office, with the average respondent there forfeiting only $71 of their salary each month in order to continue working from home.

And if we ever do return en masse to the boardroom, it seems the days of high-fives and handshakes with your coworkers are over. Results say that 75 percent of employees do not think handshakes will ever return to the work environment, and in their place should be the elbow tap (65 percent), a simple nod (28 percent), the balance-testing foot tap (5 percent), and the formal bow (a mere 2 percent).

Perhaps most telling is this result: One in three workers say that since WFH began, they have felt their bosses have been friendlier and with a more relaxed attitude toward employees. Long live the Zoom meetings.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.